Corporation (NASDAQ:NVNO), a medical device company with a market capitalization of $54.5 million, reported interim two-year follow-up data from its pivotal trial of the VenoValve, indicating ...
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
Although heart disease remains the leading cause of death in the United States, the field of heart and vascular care has undergone significant advancements in the 20 years since The Ohio State ...
Health First’s Heart & Vascular Program has earned its third straight 3-star overall isolated Coronary Artery Bypass Graft (CABG) recognition from the Society of Thoracic Surgeons (STS). [...] ...